Pancreatic Cancer Research

ResearcherIRCCS Ospedale San RaffaeleNo recent work listed

Luca Gianni

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2372-9625; OpenAlex author ID A5058537459. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
20
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 2 papers

Papers 10

  1. Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. Co-author DOI 10.1002/cam4.5893↗
  2. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  3. Multidrug regimens for treatment of older patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.dld.2020.06.006↗
  4. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00280-020-04047-7↗
  5. Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives. Co-author DOI 10.1016/j.ctrv.2018.10.013↗
  6. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreati… Last author DOI 10.1016/j.ejca.2018.07.007↗
  7. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Last author DOI 10.1016/s2468-1253(18)30081-5↗
  8. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. Last author DOI 10.1016/s2468-1253(18)30196-1↗
  9. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Last author DOI 10.1093/annonc/mdx495↗
  10. Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic… Last author DOI 10.1038/bjc.2016.209↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Silvia Matilde Zanon · 8 shared papers, 2016–2021 · strength 0.65
  2. Michele Reni · 8 shared papers, 2016–2021 · strength 0.65
  3. Marta Chiaravalli · 6 shared papers, 2017–2021 · strength 0.49
  4. Umberto Peretti · 5 shared papers, 2018–2021 · strength 0.47
  5. Marina Macchini · 5 shared papers, 2018–2021 · strength 0.47
  6. Gianpaolo Balzano · 6 shared papers, 2016–2020 · strength 0.42
  7. Massimo Falconi · 6 shared papers, 2016–2020 · strength 0.42
  8. Paolo Giorgio Arcidiacono · 5 shared papers, 2016–2020 · strength 0.35
  9. Claudio Doglioni · 5 shared papers, 2016–2018 · strength 0.31
  10. Paolo Passoni · 3 shared papers, 2016–2018 · strength 0.18
  11. Josep M. Tabernero · 1 shared paper, 2023 · strength 0.16
  12. Giuseppe Viale · 1 shared paper, 2023 · strength 0.16
  13. Elisabeth G.E. de Vries · 1 shared paper, 2023 · strength 0.16
  14. Giulia Orsi · 1 shared paper, 2020 · strength 0.11
  15. Domenico Tamburrino · 1 shared paper, 2020 · strength 0.11
  16. Stefano Partelli · 1 shared paper, 2018 · strength 0.07
  17. Stefania Mosconi · 1 shared paper, 2018 · strength 0.07
  18. Alessandro Zerbi · 1 shared paper, 2018 · strength 0.07
  19. Domenico Pinelli · 1 shared paper, 2018 · strength 0.07
  20. Stefano Crippa · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.